BIOMAT Database Logo BIOMAT Database Logo

[Treatment of the parkinsonian syndrome with L-dopa and amantadine]. 1973

G H Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprişan, and M Merling, and E Nemţeanu, and M Ciuntu, and I Koropitzer

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000547 Amantadine An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake. 1-Aminoadamantane,Adamantylamine,Adekin,Aman,Amanta,Amanta-HCI-AZU,Amanta-Sulfate-AZU,Amantadin AL,Amantadin AZU,Amantadin Stada,Amantadin-neuraxpharm,Amantadin-ratiopharm,Amantadina Juventus,Amantadina Llorente,Amantadine Hydrochloride,Amantadine Sulfate,Amixx,Cerebramed,Endantadine,Gen-Amantadine,Infecto-Flu,Infex,Mantadix,Midantan,PMS-Amantadine,Symadine,Symmetrel,Viregyt,Wiregyt,tregor,1 Aminoadamantane,AL, Amantadin,AZU, Amantadin,Amanta HCI AZU,Amanta Sulfate AZU,AmantaHCIAZU,AmantaSulfateAZU,Amantadin neuraxpharm,Amantadin ratiopharm,Amantadinneuraxpharm,Amantadinratiopharm,Gen Amantadine,GenAmantadine,Hydrochloride, Amantadine,Infecto Flu,InfectoFlu,Juventus, Amantadina,Llorente, Amantadina,PMS Amantadine,PMSAmantadine,Stada, Amantadin,Sulfate, Amantadine

Related Publications

G H Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprişan, and M Merling, and E Nemţeanu, and M Ciuntu, and I Koropitzer
[Amantadine and L-Dopa in the treatment of parkinsonian syndromes].
October 1971, Minerva medica,
G H Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprişan, and M Merling, and E Nemţeanu, and M Ciuntu, and I Koropitzer
[Modalities of treatment of Parkinsonian syndrome with L-dopa].
January 1972, International journal of neurology,
G H Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprişan, and M Merling, and E Nemţeanu, and M Ciuntu, and I Koropitzer
[Clinical considerations on therapy of parkinsonian syndromes with amantadine and L-Dopa].
October 1971, Minerva medica,
G H Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprişan, and M Merling, and E Nemţeanu, and M Ciuntu, and I Koropitzer
[L-dopa in the treatment of the Parkinsonian syndrome].
January 1973, Neurologia, psihiatria, neurochirurgia,
G H Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprişan, and M Merling, and E Nemţeanu, and M Ciuntu, and I Koropitzer
[Amantadine and L-Dopa in the treatment of parkinsonian syndromes and their implications for rehabilitation].
October 1971, Minerva medica,
G H Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprişan, and M Merling, and E Nemţeanu, and M Ciuntu, and I Koropitzer
Treatment of Parkinsonism with L-dopa and amantadine.
October 1970, Lancet (London, England),
G H Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprişan, and M Merling, and E Nemţeanu, and M Ciuntu, and I Koropitzer
The treatment of parkinsonism with L-Dopa and amantadine.
June 1970, The Journal of the Florida Medical Association,
G H Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprişan, and M Merling, and E Nemţeanu, and M Ciuntu, and I Koropitzer
[Treatment of parkinsonian states with L-dopa].
November 1971, Bulletin de l'Academie nationale de medecine,
G H Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprişan, and M Merling, and E Nemţeanu, and M Ciuntu, and I Koropitzer
Treatment of Parkinson's disease with amantadine and L-Dopa.
January 1972, European neurology,
G H Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprişan, and M Merling, and E Nemţeanu, and M Ciuntu, and I Koropitzer
Combined treatment of parkinsonism with L-dopa and amantadine.
September 1970, Lancet (London, England),
Copied contents to your clipboard!